• Basket
  • Log in

Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

New to Patents? Find out more from CambridgeIP ®

Patents »

US6994852: Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5

Share

Share on Linked In Share on Facebook Share by Email

Filing Information

Inventor(s) Robert W. Colman · Shaker A. Mousa ·
Assignee(s) Temple University-of the Commonwealth System of Higher Education · Bristol-Myers Squibb Pharma Company ·
Attorney/Agent(s) Drinker Biddle & Reath LLP ·
Primary Examiner Gary B. Nickol ·
Application Number US10129946
Filing date 11/10/2000
PCT 371 date 05/10/2002
Issue date 02/07/2006
Predicted expiration date 10/22/2022
Patent term adjustment 711
U.S. Classifications 424/130.1  · 424/141.1  · 424/139.1  · 424/155.1  · 424/138.1  ·
International Classifications A61K39395  ·
Kind CodeB1
Related U.S. Application DataThis is a 371 of International Patent Application PCT/US00/30975, filed Nov. 10, 2000, now abandoned, which claims priority from U.S. provisional patent application 60/165,165, filed Nov. 12, 1999.
PCT Application Number WO20PCTUS0030975 - 11/10/2000
PCT Publication Number WO200134195 - 05/17/2001
18 Claims, 8 Drawings


Abstract

Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.

Independent Claims | See all claims (18)

  1. 1. A method for inhibiting angiogenesis comprising administering to a mammal an effective amount of an antibody against an antigenic determinant of high molecular weight kininogen domain 5.
  2. 10. A method for inhibiting endothelial cell proliferation comprising contacting endothelial cells with an effective concentration of an antibody against an antigenic determinant of high molecular weight kininogen domain 5.
  3. 13. A method for inhibiting tumor growth or formation in a mammal comprising administering to said mammal an effective amount of an antibody against an antigenic determinant of high molecular weight kininogen domain 5.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4908431 Temple University-of the Commonwealth System of Higher Education Colman et al. Mar 1990
US5596079 Smith et al. Jan 1997
US5756291 Gilead Sciences, Inc. Griffin et al. May 1998
US5786365 Hoechst Aktiengesellschaft Heitsch et al. Jul 1998
US5800385 Omeros Medical Systems, Inc. Demopulos et al. Sep 1998
US5817748 The Research Foundation of State University of New York Miller et al. Oct 1998
US5830671 Mount Sinai Hospital Corporation Dennis et al. Nov 1998
US5846720 Oncogene Science, Inc. Foulkes et al. Dec 1998
US5846821 Trustees of Dartmouth College Guerinot et al. Dec 1998
US6245886 Bayer Corporation Halazonetis et al. Jun 2001

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
JP7082172Mar 1995
JP8208692Aug 1996
WO199625434Aug 1996
WO199641640Dec 1996
WO199705258Feb 1997
WO200027866TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OFMay 2000

Other Publications

Granziero et al. (Eur. J. Immunol. 1999, 29:1127-1138).*
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).*
Lottspeich et al., “The Amino Acid Sequence of the Light Chain of Human High-Molecular-Mass Kininogen”, European Journal of Biochemistry, 1985, vol. 152, pp. 307-314.
Takagaki et al., Cloning and Sequence Analysis of cDNAs for Human High Molecular Weight and Low Molecular Weight Prekininogens, The Journal of Biological Chemistry, Jul. 15, 1985, vol. 260, No. 14, pp. 8601-8609.
Kitamura et al., “Structural Organization of Human Kininogen Gene and a Model for its Evolution”, The Journal of Biological Chemistry, Jul. 15, 1985, vol. 260, No. 15, pp. 8610-8617.
Shariat-Madar et al., “Kininogen-Cytokeratin 1 Interactions in Endothelial Cell Biology”, TCM, vol. 9, No. 8, 1999.
Reddigari, et al., “Human High Molecular Weight Kininogen Binds to Human Umbilical Vein Endothelial Cells Via its Heavy and Light Chains”, The American Society of Hematology, Blood, vol. 81, No. 5 (Mar. 1), 1993, pp 1306-1311.
Auerswald et al., “Cloning, Expression, And Characterization Of Human Kininogen Domain 3”, FEBS Letters vol. 321, No. 1, pp. 93-97, 1993.
Colman et al., Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes. Blood, 90(10):3819-3843 (Nov. 15, 1997).
R.W. Colman, et al., Abstract #701,“Inhibition Of Angiogenesis By Peptides Derived From Kininogen”, Blood vol. 92, No. 10 Supplement 1, Nov. 15, 1998.
Heiko Herwald, et al., “Identification of an Endothelial Cell Binding Site on Kininogen Domain D3”, The Journal of Biological Chemistry, vol. 270, No. 24, pp. 14634-14641 (Jun. 16, 1995).
Satya P. Kunapuli et al.,“Deletion Mutagenesis of High Molecular Weight Kininogen Light Chain”, The Journal of Biological Chemistry vol. 268, No. 4, pp. 2486-2492 (Feb. 5, 1993).
Ahmed A.K. Hasan, et al., “Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5”, The Journal of Biological Chemistry, vo. 270, No. 33 pp. 19256-19261 (Aug. 18, 1995).
Robert W. Colman, et al., “Binding of High Molecular Weight Kininogen to Human Endothelial Cells Is Mediated via a Site within domains 2 and 3 of the Urokinase Receptor”, J. Clin. Invest., vol. 100, No. 6, pp. 1481-1487 (Sep. 1997).
A.K. Hasan, et al., “The Carboxyl Terminus of Bradykinin and Amino Terminus of the Light Chain of Kininogens comprise an Endothelial Cell Binding Domain”, Ahmed The Journal of Biological Chemistry, vo. 269, No. 50, pp. 31822-31830 (Dec. 16, 1994).
Mohammad M.H. Khan et al.,“Three noncintiguous peptides comprise binding sites on high-molecular-weight kininogen to neutrophils”, The American Physiological Society (Heart Circ. Physiol. 44): H145-150, vol. 275 (1998).
Yanina T. Wachtfogel et al.,“High Molecular Weight Kininogen Binds to Mac-I on Neutrophils by Its Heavy Chain (Domain 3) and Its Light Chain (Domain 5)”, The Journal of Biological Chemistry, vol. 269, No. 30, pp. 19307-19312 (Jul. 29, 1994).
Shinji Asakura et al., “Inhibition of Cell Adhesion by High Molecular Weight Kininogen”, The Journal of Cell Biology, vol. 116, No. 2, pp. 465-476 (Jan. 1992).
Colman et al., Domain 5 of High Molecular Weight Kininogen (Kininostatin) Down-Regulates Endothelial Cell Proliferation and Migration and Inhibits Angiogenesis. Blood, Jan. 15, 2000, vol. 95, No. 2, pp 543-550.
Jörg Kaufmann et al., “Structural Dissection of the Multidomain Kininogens”, The Journal of Biological Chemistry, vol. 268, No. 12, Apr. 25, pp. 9079-9091.
Alvin H. Schmaier et al., “Determination of the Bifunctional Properties of High Molecular Weight Kininogen by Studies with Monoclonal Antibodies Directed to Each of Its Chains”, The Journal of Biological Chemistry, vol. 262, No. 3, Issue of Jan. 25, pp 1405-1411, 1987.
Sesha R. Reddigari, et al., “Monoclonal Antibody to Human High-Molecular-Weight Kininogen Recognizes Its Prekallikrein Binding Site and Inhibits Its Coagulant Activity”, Blood, vol. 74, No. 2, Aug. 1, 1989, pp. 695-702.
* cited by examiner

Referenced By

The current document is not referenced by other documents.